Abstract. MicroRNA (miR)-195 has been reported to be a tumor suppressor. Downregulation of miR-195 has been shown to correlate with lymph node metastasis and poor prognosis in colorectal cancer. However, the specific regulatory role of miR-195 in colorectal cancer cells is yet to be elucidated. In the present study, miR-195 expression was significantly reduced in colorectal cancer tissues. Furthermore, CARMA3 was identified as a novel target of miR-195, which was observed to be upregulated in colorectal cancer. In addition, downregulation of miR-195 increased CARMA3 protein expression, whereas miR-195 upregulation suppressed CARMA3 protein expression in SW480 and HT29 colorectal cancer cells. Moreover, overexpression of miR-195 downregulated cell proliferation, colony-formation and invasion in SW480 and HT29 cells, which was reversed upon CARMA3 overexpression. In conclusion, the findings of the present study suggest that miR-195 has a suppressive role in colorectal cancer cells through directly targeting CARMA3. Therefore, CARMA3 may be a potential target for the treatment of colorectal cancer.
Introduction
Colorectal cancer, one of the most common types of cancer in males and females, is a serious demographic and economic problem worldwide (1) . The development and progression of colorectal cancer are regulated by a complex cascade of molecular events, which are involved in cell proliferation and invasion (2) . Therefore, it is of great importance to explore the molecular mechanisms underlying colorectal carcinogenesis.
MicroRNAs (miRNAs) are a type of endogenous non-coding RNA, which act as endogenous suppressors of translation by directly binding to the 3' untranslated region (UTR) of target mRNAs (3) . Recently, numerous miRNAs have been shown to be involved in the development and progression of colorectal cancer (4) . For example, miR-133a has been observed to suppress colorectal cancer through activating the p53/p21 signaling pathway (5) , and the inhibition of miR-21 has been found to enhance the susceptibility of chemoresistant colon cancer cells to therapeutic treatment (6) . Therefore, miRNAs may be promising candidates or targets for colorectal cancer therapy.
miR-195, a member of the miR-16/15/195/424/497 family, has been demonstrated to act as a tumor suppressor in numerous types of malignant human tumors (7). Yang et al (8) found that miR-195 induced apoptosis in hepatocellular carcinoma cells in vitro through targeting LATS2 (8) . Furthermore, Mao et al (9) showed that miR-195 suppressed osteosarcoma cell invasion and migration in vitro through downregulating FASN. Moreover, Ding et al (10) proposed that miR-195 may exert its tumor suppressive function by downregulating numerous nuclear factor (NF)-κB) downstream effectors through directly targeting IKK α and TAB. In addition, miR-195 has been found to enhance the sensitivity of cancer cells to chemotherapy, with Yang et al (11) showing that upregulation of miR-195 increases the sensitivity of breast cancer cells to adriamycin through targeting Raf-1.
CARMA3, also known as CARD10, is a member of the CARMA family, as are the other two members CARMA1 (CARD11) and CARMA2 (CARD14). These three proteins share similar structural motifs, including CARD, coiled-coil, PDZ, SRC homology 3 and guanylate kinase-like domains (12) . As a scaffold protein, CARMA3 has been demonstrated to have an important role in tumorigenesis (13) . Recently, CARMA3 was found to be overexpressed in colorectal cancer and to contribute to colorectal cancer cell growth by promoting cell cycle progression through NF-κB-mediated upregulation of cyclin D1 (14) .
However, the specific roles and underlying molecular mechanisms of miR-195 and CARMA3 in colorectal cancer cells are yet to be elucidated. The present study determined the expression of miR-195 and CARMA3 in colorectal cancer tissues and their matched adjacent tissues. CARMA3 was identified to be a novel target of miR-195. Moreover, the regulatory roles of CARMA3 and miR-195 in cell proliferation, colony-formation and invasion were investigated in colorectal cancer cells in vitro.
MicroRNA-195 inhibits colorectal cancer cell proliferation, colony-formation and invasion through targeting CARMA3 Materials and methods
Tissue specimen collection. The protocols used in the present study were approved by the Ethical Committee of Central South University (Changsha, China). Twenty colorectal cancer and matched adjacent tissues were obtained from the Department of General Surgery, the Third Xiangya Hospital of Central South University (Changsha, China) between September 2012 and March 2013. Informed consent was obtained from each patient included in this study. Each tissue sample was immediately frozen in liquid nitrogen following surgical removal.
Cell culture. SW480 and HT29 human colorectal cancer cell lines were obtained from the Cell Bank of Central South University (Changsha, China). Cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 IU/ml penicillin and 100 µg/ml streptomycin sulfate at 37˚C in a humidified incubator containing 5% CO 2 .
RNA extraction and quantitative polymerase chain reaction (qPCR) analysis. Total RNA was extracted using TRIzol ® reagent (Invitrogen Life Technologies, Carlsbad, CA, USA), according to the manufacturer's instructions. qPCR analysis was performed to assess mRNA expression using a TaqMan ® Reverse Transcription kit and a Power SYBR ® Green kit (Ther mo Fisher Scientific, Waltham, MA, USA). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an endogenous control. For the analysis of miRNA expression, 10 ng RNA was converted to cDNA using the Applied Biosystems ® TaqMan ® MicroRNA Reverse Transcription kit (Applied Biosystems, Carlsbad, CA, USA). qPCR was performed using the Applied Biosystems 7500 thermocycler (Applied Biosystems). U6 expression was used as an endogenous control. Relative mRNA and miRNA expression were analyzed using the 2 -ΔΔCt method. The following primers were used in the qPCR analysis: Forward: 5'-CTGTGGGAGCGAATCGAGG-3' and reverse: 5'-CAG CGCAAGATGTCCATCA-3' for CARMA3; and forward: 5'-CTGGGCTACACTGAGCACC-3' and reverse: 5'-AAG TGGTCGTTGAGGGCAATG-3' for GAPDH. The primer sequences used to detect anti-matrix metalloproteinase (MMP)-9 were as follows: Forward: 5'-TGTACCGCTATG GTTACACTCG-3'; and reverse: 5'-GGCAGGGACAGTTGCT TCT-3'.
Western blot analysis. Tissues and cells were lysed in cold radioimmunoprecipitation assay lysis buffer. Proteins were separated using 10% SDS-PAGE and transferred onto polyvinylidene difluoride (PVDF) membranes (Invitrogen Life Technologies), which were then incubated with trisbuffered saline and Tween-20 containing 5% skimmed milk at 4˚C overnight. Membranes were then incubated with anti-CARMA3, and anti-GAPDH primary antibodies (Abcam PLC., Cambridge, UK), at room temperature for 3 h. Subsequent to washing with phosphate-buffered saline and Tween-20 three times, PVDF membranes was incubated for 1 h with corresponding rabbit anti-mouse horseradish peroxidase-conjugated secondary antibodies (Abcam PLC.). Chemiluminescent detection was performed using an enhanced chemiluminescence kit (Pierce Chemical Co., Rockford, IL, USA). Image-Pro Plus 6.0 software (Media Cybernetics, Inc., Rockville, MD, USA) was used to analyze the relative target gene protein expression, which was normalized using GAPDH protein expression. The wild type 3' UTR of CARMA3 and the mutant 3' UTR of CARMA3 were then inserted into the psiCHECK™-2 Vector (Promega Corporation, Madison, WI, USA). SW480 and HT29 cells were cultured to approximately 50-60% confluence on 24-well plates, prior to co-transfection with psiCHECK™-2-CARMA3-3' UTR or psiCHECK™-2-mutant CARMA3-3' UTR vector, with or without 50 nM miR-195, using the Cellfectin ® II Reagent (Invitrogen Life Technologies). The luciferase activity was assessed 48 h following transfection using a Beckman Coulter LD 400 luminometer (Beckman Coulter Inc., Fullerton, CA, USA). Renilla luciferase activity was normalized to firefly luciferase activity.
Tra nsfection. Tra nsfection was per for med using
Cell proliferation assay. The MTT assay was used to measure cell proliferation. At 48 h post-transfection, the transfection medium in each well was replaced with 100 µl fresh serum-free medium containing 0.5 g/l MTT. Subsequent to incubation at 37˚C for 4 h, the MTT medium was removed by aspiration and 50 µl dimethylsulfoxide was added to each well. Following incubation at 37˚C for a further 10 min, the optical density at 570 nm was measured using the Bio-Tek™ ELX-800™ Absorbance Microplate reader (Biotek, Winooski, VT, USA). This experiment was repeated three times.
Cell invasion assay. A cell suspension containing 5x10
5 cells/ml was prepared using serum-free DMEM. For the cell invasion assay, 500 µl DMEM containing 10% FBS was added to the upper chamber. Following incubation at 37˚C with 5% CO 2 for 24 h, the non-invading cells and the extracellular matrix gel were gently removed. Cells that had invaded through the membrane were stained for 20 min, washed with water and then dried in air. Five fields were randomly selected and the number of cells which had invaded through the membrane were counted using a microscope (MVX10; Olympus, Tokyo, Japan).
Statistical analysis. All data are presented as the mean ± standard deviation of at least three independent samples. Statistical analysis was performed using one-way analysis of variance or Student's t-tests using SPSS 19.0 (SPSS, Inc., IBM, Armonk, NY, USA) software. P<0.05 was considered to indicate a statistically significant difference.
Results

miR-195 expression is downregulated in colorectal cancer
tissues. miR-195 expression was determined in human colorectal cancer tissues and their matched adjacent tissues. As shown in Fig. 1 , the expression of miR-195 was found to be increased in colorectal cancer tissues compared with their matched adjacent tissues. This finding suggests that miR-195 upregulation may have a role in colorectal cancer.
CARMA3 is a novel target of miR-195.
Bioinformatic predication showed that the putative binding site for miR-195 at the 3' UTR of CARMA3 is highly conserved. In the present study, a mutant CARMA3 3' UTR was generated ( Fig. 2A) . As shown in Fig. 2B , luciferase activity was significantly reduced following co-transfection with the wild type CARMA3 3' UTR and miR-195 in SW480 and HT29 cells (P<0.01). However, the luciferase activity in other groups showed no significant differences. These findings suggest that CARMA3 is a novel target of miR-195 in SW480 and HT29 colorectal cancer cells.
CARMA3 expression is increased in colorectal cancer tissues.
qPCR analysis was performed in order to determine the expression of CARMA3 in human colorectal cancer and matched adjacent normal tissues. As shown in Fig. 3 , CARMA3 mRNA expression was observed to be downregulated in colorectal cancer tissues compared with the matched adjacent tissues. This suggests that CARMA3 may have a suppressive role in colorectal cancer. Recently, Feng et al (15) reported that CARMA3 promoted glioma cell invasion through MMP-9, a key tumor invasion factor. Thus, to investigate the mechanism by which miR-195 regulates colorectal cancer cell invasion, MMP-9 mRNA expression was assessed in each group. As shown in Fig. 7B , MMP-9 expression was significantly reduced in the SW480 and HT29 cells overexpressing miR-195, while significantly increased in the cells with downregulated miR-195 expression. 
Discussion
It is well established that miRNAs have a crucial role in the regulation of various human malignancies, due to their capacity to regulate the expression of numerous target genes, which are associated with tumorigenesis, tumor progression, metastasis and sensitivity to chemotherapy (16) (17) (18) . The development and progression of colorectal cancer has been shown to be mediated by complex molecular events, which monitor cell proliferation and motility (19) . In the present study, miR-195 downregulation was found to correlate with CARMA3 upregulation in colorectal cancer tissues. It has been demonstrated that miR-195 is involved in colorectal cancer (20) (21) (22) (23) . Wang et al (21) showed that miR-195 was downregulated in colorectal cancer tissues, which is consistent with the findings of the present study. Moreover, Wang et al (21) showed that the downregulation of miR-195 in colorectal cancer was correlated with lymph node metastasis and poor prognosis, indicating that miR-195 may have the potential to be an independent marker for the predication of clinical outcome in patients with colorectal cancer. In addition, miR-195 has been found to promote apoptosis and suppress tumorigenicity in human colorectal cancer cells through targeting Bcl-2, an important anti-apoptotic gene (22) . Furthermore, miR-195 has been reported to enhance the susceptibility of colorectal cancer cells to the chemotherapeutic drug doxorubicin through directly inhibiting the expression of the BCL2L2(23). These findings suggest that miR-195 has an 
B
A inhibitory role in colorectal cancer and may be a promising therapeutic candidate for colorectal cancer.
A single miRNA is capable of regulating numerous target genes; therefore, in the present study it was hypothesized that other genes may also be involved in miR-195-mediated biological processes in colorectal cancer cells. In order to investigate this hypothesis, bioinformatic analyses were performed and CARMA3 was identified to be a target of miR-195. A luciferase reporter assay further confirmed that CARMA3 was a target of miR-195 in colorectal cancer cells. CARMA3 has recently been shown to have an oncogenic role in the progression of several human malignancies (12) (13) (14) 24, 25) . Wu et al (24) showed that CARMA3 was upregulated in renal cell carcinoma and that its overexpression may be an independent prognostic indicator of survival in patients with renal cell carcinoma. Furthermore, Li et al (12) reported that overexpression of CARMA3 in non-small-cell lung cancer is associated with tumor progression. Recently, Miao et al (14) reported that CARMA3 was overexpressed in colorectal cancer, consistent with the findings of the present study. Miao et al (14) also found that the overexpression of CARMA3 in colorectal cancer was associated with tumor-node-metastasis stage, lymph node metastasis and Ki67 proliferation index, indicating that CARMA3 may act as an oncogene in colorectal cancer. CARMA3 was also found to enhance colorectal cancer cell proliferation in vitro, by promoting cell cycle progression through NF-κB-induced upregulation of cyclin D1 (14) . However, the role of CARMA3 and miRNAs in the regulation of colorectal cancer is yet to be elucidated. Therefore, in the present study, the interelation between miR-195 and CARMA3 was investigated in colorectal cancer cells. miR-195 overexpression was found to significantly downregulate CARMA3 protein expression, while inhibition of miR-195 was observed to significantly promote CARMA3 protein expression in colorectal cancer cells. These findings suggest that miR-195 negatively regulates CARMA3. Moreover, these findings suggest that miR-195 inhibited colorectal cancer cell proliferation, colony-formation and invasion through directly suppressing CARMA3 expression.
CARMA3 has previously been reported to be required for G protein-coupled receptor induced NF-κB activation, which participates in the regulation of MMP-9, a key promoter of cancer cell invasion (26, 27) . Therefore, in the present study the expression of MMP-9 was assessed. MMP-9 mRNA expression was found to correlate with colorectal cancer cell invasion, indicating that the inhibitory effect of miR-195 on colorectal cancer cell invasion may at least partially be mediated through the downregulation of MMP-9, by directly targeting CARMA3. In accordance with these findings, Feng et al (15) reported that CARMA3 promoted glioma cell invasion through upregulating the expression of MMP-9.
In conclusion, the present study demonstrates that miR-195 inhibits colorectal cancer cell proliferation, colony formation and invasion, at least partially through targeting CARMA3. These findings suggest that miR-195 may be a potential candidate for the treatment of colorectal cancer.
